Viking Therapeutics (VKTX) Competitors $27.68 +0.43 (+1.59%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VKTX vs. RDY, VTRS, MRNA, ASND, QGEN, ROIV, RVMD, ELAN, BPMC, and BBIOShould you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Viking Therapeutics vs. Dr. Reddy's Laboratories Viatris Moderna Ascendis Pharma A/S Qiagen Roivant Sciences Revolution Medicines Elanco Animal Health Blueprint Medicines BridgeBio Pharma Viking Therapeutics (NASDAQ:VKTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk. Does the MarketBeat Community prefer VKTX or RDY? Viking Therapeutics received 313 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 80.08% of users gave Viking Therapeutics an outperform vote while only 59.41% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformViking TherapeuticsOutperform Votes63580.08% Underperform Votes15819.92%Dr. Reddy's LaboratoriesOutperform Votes32259.41% Underperform Votes22040.59% Which has more risk and volatility, VKTX or RDY? Viking Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Do analysts rate VKTX or RDY? Viking Therapeutics currently has a consensus target price of $87.15, indicating a potential upside of 219.83%. Dr. Reddy's Laboratories has a consensus target price of $17.00, indicating a potential upside of 18.59%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Viking Therapeutics is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals believe in VKTX or RDY? 76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 4.1% of Viking Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to VKTX or RDY? In the previous week, Viking Therapeutics had 4 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 12 mentions for Viking Therapeutics and 8 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.63 beat Viking Therapeutics' score of 1.43 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has higher earnings and valuation, VKTX or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$109.96M-$1.15-23.70Dr. Reddy's Laboratories$325.54B0.04$668M$0.6621.72 Is VKTX or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 17.25% compared to Viking Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Viking Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -11.93% -11.57% Dr. Reddy's Laboratories 17.25%17.87%12.32% SummaryViking Therapeutics beats Dr. Reddy's Laboratories on 10 of the 18 factors compared between the two stocks. Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VKTX vs. The Competition Export to ExcelMetricViking TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.02B$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-26.909.0426.7819.69Price / SalesN/A253.23386.97118.34Price / CashN/A65.8538.2534.62Price / Book7.716.406.744.50Net Income-$109.96M$143.98M$3.23B$248.32M7 Day Performance-2.04%1.90%1.49%-0.03%1 Month Performance5.34%4.01%11.47%12.72%1 Year Performance-57.40%-3.00%16.57%7.38% Viking Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VKTXViking Therapeutics4.4105 of 5 stars$27.68+1.6%$87.15+214.8%-57.6%$3.11BN/A-27.6820Positive NewsGap UpRDYDr. Reddy's Laboratories2.329 of 5 stars$14.41-0.2%$17.00+18.0%+4.0%$12.03B$325.54B22.9524,800Positive NewsGap UpVTRSViatris2.0839 of 5 stars$8.76-0.9%$10.50+19.9%-22.6%$10.28B$14.33B-11.8437,000Trending NewsMRNAModerna4.533 of 5 stars$26.42+6.3%$53.95+104.2%-82.0%$10.22B$3.14B-2.853,900Trending NewsAnalyst ForecastASNDAscendis Pharma A/S3.3608 of 5 stars$158.81+0.8%$216.07+36.1%+28.7%$9.68B$368.70M-22.37640QGENQiagen3.9868 of 5 stars$42.66+0.0%$48.42+13.5%-3.5%$9.48B$2.00B118.796,030Positive NewsROIVRoivant Sciences2.1443 of 5 stars$10.80+0.1%$17.50+62.0%-2.8%$7.71B$122.59M-72.00860Positive NewsUpcoming EarningsRVMDRevolution Medicines4.3629 of 5 stars$39.530.0%$67.08+69.7%-2.3%$7.36B$742,000.00-11.01250Positive NewsELANElanco Animal Health3.5038 of 5 stars$13.17+1.9%$15.17+15.2%-24.4%$6.54B$4.43B32.939,800Analyst ForecastBPMCBlueprint Medicines2.6438 of 5 stars$100.55-1.1%$126.56+25.9%-2.0%$6.49B$562.12M-93.10640Positive NewsInsider TradeBBIOBridgeBio Pharma4.5971 of 5 stars$33.49-1.0%$57.09+70.5%+12.2%$6.36B$127.42M-11.75400Positive NewsInsider Trade Related Companies and Tools Related Companies Dr. Reddy's Laboratories Competitors Viatris Competitors Moderna Competitors Ascendis Pharma A/S Competitors Qiagen Competitors Roivant Sciences Competitors Revolution Medicines Competitors Elanco Animal Health Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VKTX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VKTX Stock Free VKTX Stock Alerts